This section highlights FDA-related milestones and regulatory updates for drugs developed by Vertex Pharmaceuticals (VRTX).
Over the past two years, Vertex Pharmaceuticals has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
suzetrigine, CASGEVY, ALYFTREK, povetacicept, Vanzacaftor/Tezacaftor/Deutivacaftor,, inaxaplin, and VX-993. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
Suzetrigine FDA Regulatory Timeline and Events
Suzetrigine is a drug developed by Vertex Pharmaceuticals for the following indication: For the Treatment of Moderate-to-Severe Acute Pain.
This drug is approved by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- suzetrigine
- Announced Date:
- May 21, 2026
- Indication:
- For the Treatment of Moderate-to-Severe Acute Pain
Announcement
Vertex Pharmaceuticals announced that Health Canada has accepted for review a New Drug Submission (NDS) for suzetrigine for the treatment of moderate-to-severe acute pain in adults. Suzetrigine is a selective NaV1.8 pain signal inhibitor that represents a new class of oral pain medicine; it is not an opioid or a nonsteroidal anti-inflammatory drug (NSAID).
AI Summary
Vertex Pharmaceuticals said Health Canada has accepted for review its New Drug Submission for suzetrigine, a new oral pain medicine for adults with moderate-to-severe acute pain. Suzetrigine is designed to block NaV1.8, a pain signal target found in nerve cells that send pain messages. The company says this makes it a different kind of treatment from opioids and NSAIDs. Vertex believes the medicine could help many Canadians who deal with acute pain each year.
Suzetrigine is described as a selective NaV1.8 pain signal inhibitor and the first oral drug in this class. The company says the target is linked to pain control and is not found in the human brain, which may help reduce addiction concerns. Vertex also said the medicine has shown a favorable benefit-risk profile in clinical studies.
Read Announcement- Drug:
- suzetrigine
- Announced Date:
- July 14, 2025
- Indication:
- For the Treatment of Moderate-to-Severe Acute Pain
Announcement
Vertex Pharmaceuticals Incorporated announced that it has been named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc., a leading health care improvement company.
AI Summary
Vertex Pharmaceuticals was recently honored by Premier, Inc., a respected health care improvement company, as a 2025 Breakthroughs Innovation Celebration winner. This award recognizes the company’s commitment to developing innovative solutions for patients with significant unmet needs, highlighting their work on JOURNAVX™, a novel oral, non-opioid pain management drug. JOURNAVX™ is designed as a highly selective NaV1.8 pain signal inhibitor for adults suffering from moderate-to-severe acute pain. Vertex’s breakthrough in pain management is seen as a significant advancement in healthcare, especially since it offers a non-opioid alternative – a rare feat in modern pain therapies. The recognition by Premier, Inc. underscores Vertex’s dedication to operational excellence and improving patient outcomes. The company will receive formal accolades for this achievement at the upcoming 2025 Breakthroughs Conference and Exhibition.
Read Announcement- Drug:
- suzetrigine
- Announced Date:
- January 30, 2025
- Indication:
- For the Treatment of Moderate-to-Severe Acute Pain
Announcement
Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain.
AI Summary
Vertex Pharmaceuticals Incorporated announced that the U.S. FDA has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for treating adults with moderate-to-severe acute pain. This approval marks a significant step in pain management by providing a new treatment option that avoids the risks often associated with opioid therapies.
JOURNAVX works by selectively blocking NaV1.8 channels, which are key in transmitting pain signals in the body. By targeting these channels, the drug offers effective pain relief while minimizing common side effects linked to traditional pain medications. Vertex’s new approval highlights their commitment to addressing serious unmet needs in pain therapy and improving patient quality of life with innovative, non-opioid solutions.
Read Announcement- Drug:
- suzetrigine
- Announced Date:
- December 19, 2024
- Indication:
- For the Treatment of Moderate-to-Severe Acute Pain
Announcement
Vertex Pharmaceuticals Incorporated announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy (LSR).
AI Summary
Vertex Pharmaceuticals announced positive Phase 2 results for suzetrigine, its investigational oral drug that selectively inhibits the NaV1.8 channel to reduce pain in patients with painful lumbosacral radiculopathy (LSR). In the study, the suzetrigine group achieved a statistically significant 2.02-point reduction in pain on the Numeric Pain Rating Scale at Week 12. While the placebo group experienced a 1.98-point reduction, post-hoc analyses suggest that differences in placebo responses across study sites may have masked the true treatment effect. The drug was generally well tolerated, with adverse events mostly mild to moderate and no serious events linked to suzetrigine. Vertex plans to address the placebo response challenge by innovating the design of its upcoming Phase 3 trial, pending discussions with regulators. An investor call to discuss these findings is scheduled for December 19 at 8:00 a.m. ET.
Read Announcement- Drug:
- suzetrigine
- Announced Date:
- July 30, 2024
- Target Action Date:
- January 30, 2025
- Indication:
- For the Treatment of Moderate-to-Severe Acute Pain
Announcement
Vertex Pharmaceuticals Incorporated announced that The FDA has granted suzetrigine priority review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2025
AI Summary
Vertex Pharmaceuticals announced that the FDA has granted priority review for suzetrigine, an investigational non-opioid pain signal inhibitor, and set a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2025. This decision highlights the promise of suzetrigine as a potentially transformative treatment for moderate-to-severe acute pain, a condition that affects millions of patients annually. By focusing on selective inhibition of the NaV1.8 sodium channel, suzetrigine could provide effective pain relief without the risks associated with opioid medications.
The FDA’s granting of priority review underscores the high unmet need in acute pain management and supports Vertex’s efforts to develop innovative therapies. This milestone moves the company one step closer to offering a new class of pain treatment that addresses both the efficacy challenges of non-opioid options and the adverse effects linked to opioid use.
Read Announcement- Drug:
- suzetrigine
- Announced Date:
- July 30, 2024
- Indication:
- For the Treatment of Moderate-to-Severe Acute Pain
Announcement
Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submission for suzetrigine, an investigational, oral, selective NaV1.8 pain signal inhibitor to treat moderate-to-severe acute pain. Suzetrigine has the potential to be the first new class of medicine to treat acute pain in over twenty years.
AI Summary
Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application for suzetrigine. This investigational, oral, selective NaV1.8 pain signal inhibitor is designed to treat moderate-to-severe acute pain. If approved, suzetrigine could be the first medicine in a new class for treating acute pain in over twenty years.
The FDA’s acceptance of the NDA also comes with a priority review, with a Prescription Drug User Fee Act (PDUFA) target action date set for January 30, 2025. This decision highlights the need for new, non-opioid pain management options since many current treatments either have limited effectiveness or carry risks such as addiction. Vertex’s advancement of suzetrigine marks an important step in addressing this unmet medical need for millions of patients suffering from acute pain.
Read Announcement
CASGEVY FDA Regulatory Timeline and Events
CASGEVY is a drug developed by Vertex Pharmaceuticals for the following indication: For the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT).
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- CASGEVY
- Announced Date:
- May 6, 2026
- Indication:
- For the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
Announcement
Vertex Pharmaceuticals Incorporated announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). This agreement secures sustainable access to this innovative one-time treatment for eligible patients in Germany ages 12 years and older living with severe sickle cell disease or transfusion-dependent beta thalassemia.
AI Summary
Vertex Pharmaceuticals announced a reimbursement agreement with the GKV‑Spitzenverband for CASGEVY® (exagamglogene autotemcel), its one‑time CRISPR/Cas9 gene‑edited therapy. The deal secures sustainable access in Germany for eligible patients aged 12 and older living with severe sickle cell disease (SCD) or transfusion‑dependent beta thalassemia (TDT). By covering this advanced, potentially curative treatment through the statutory health system, the agreement aims to remove a major barrier for patients who meet clinical criteria.
Germany now joins a growing list of countries that have reimbursed CASGEVY, including Austria, Denmark, Italy, the Kingdom of Saudi Arabia, the United Arab Emirates, the United Kingdom and the United States. Vertex said it will continue working with governments and payers worldwide to expand sustainable access for eligible patients who might benefit from this one‑time gene‑editing therapy.
Read Announcement- Drug:
- CASGEVY
- Announced Date:
- December 6, 2025
- Indication:
- For the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
Announcement
Vertex Pharmaceuticals Incorporated announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT).
AI Summary
Vertex announced data showing clinical benefits of CASGEVY (exagamglogene autotemcel) in people ages 5 and older with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The company presented the first pivotal results in children ages 5–11, alongside longer-term data in older patients.
In the 5–11 SCD study, 11 children were dosed and all 4 with sufficient follow-up met the primary endpoint of being free from vaso-occlusive crises for at least 12 consecutive months (VF12); no patient had a VOC after infusion, with the longest VOC-free period about two years.
In the 5–11 TDT study, 13 children were dosed and all 6 with sufficient follow-up met the primary endpoint of transfusion independence for at least 12 months with hemoglobin ≥9 g/dL (TI12); 12 of 13 are transfusion free. One patient died from pneumonia with severe veno-occlusive disease related to busulfan conditioning.
The safety profile in younger patients matched expectations for myeloablative conditioning and autologous transplant. Children showed durable increases in fetal hemoglobin and stable gene editing. Longer-term data in patients 12 and older showed VF12 in 100% (45/45) and TI12 in 98.2% (55/56) with multi-year benefit. Vertex expects to begin global regulatory filings for ages 5–11 in the first half of 2026.
Read Announcement- Drug:
- CASGEVY
- Announced Date:
- September 18, 2025
- Indication:
- For the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
Announcement
Vertex Pharmaceuticals announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel).
AI Summary
Vertex Pharmaceuticals announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) that will allow eligible patients with transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD) to access CASGEVY® (exagamglogene autotemcel), a one-time CRISPR/Cas9 gene-edited therapy.
Italy has about 5,000 people aged 12 and older living with TDT – the largest group in Europe – and around 2,300 with SCD. The agreement may give many of them access to a one-time curative therapy.
CASGEVY is Europe’s first gene-editing therapy for TDT and SCD. It edits a patient’s stem cells with CRISPR/Cas9 to boost fetal hemoglobin, cutting transfusion needs and painful crises.
Italy joins Austria, Bahrain, Denmark, England, Saudi Arabia and the United Arab Emirates in signing a reimbursement deal for CASGEVY. Vertex is partnering with health agencies worldwide to expand access to this one-time therapy for eligible patients.
Read Announcement- Drug:
- CASGEVY
- Announced Date:
- December 8, 2024
- Indication:
- For the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
Announcement
Vertex Pharmaceuticals Incorporated announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT).
AI Summary
Vertex Pharmaceuticals announced longer-term global clinical trial data for CASGEVY™ (exagamglogene autotemcel), the first approved CRISPR/Cas9 gene-edited therapy for patients with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The latest results show that CASGEVY delivers durable clinical benefits, with SCD patients having a median follow-up of 33.2 months and TDT patients 38.1 months. In these studies, most evaluable patients experienced significant improvements—including extended periods free of vaso-occlusive crises for SCD patients and long-term transfusion independence for those with TDT.
The data, presented at the American Society of Hematology Annual Meeting, confirms that the positive effects of CASGEVY are maintained over time. The therapy’s safety profile is consistent with the associated busulfan conditioning and autologous stem cell transplant, supporting its continued progress in reaching patients worldwide.
Read Announcement- Drug:
- CASGEVY
- Announced Date:
- September 25, 2024
- Indication:
- For the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
Announcement
Vertex Pharmaceuticals announced Health Canada has granted Marketing Authorization for PrCASGEVY® (exagamglogene autotemcel), an autologous genome edited hematopoietic stem cell-based therapy, for the treatment of patients 12 years of age and older with sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). There are an estimated 2,000 patients eligible for CASGEVY in Canada, the majority of whom are living with SCD.
AI Summary
Vertex Pharmaceuticals has announced that Health Canada has granted marketing authorization for PrCASGEVY® (exagamglogene autotemcel), a CRISPR-based gene-editing therapy. This innovative treatment is designed for patients aged 12 and older who suffer from sickle cell disease (SCD) with recurrent vaso-occlusive crises or have transfusion-dependent beta thalassemia (TDT). The therapy uses the patient’s own hematopoietic stem cells that are edited to boost the production of fetal hemoglobin, which may help reduce the severe pain and complications associated with these conditions.
There are about 2,000 eligible patients for CASGEVY across Canada, with most living with SCD. Vertex is working closely with hospitals and health authorities to create a network of authorized treatment centers, aiming to provide rapid access to this promising, one-time treatment for those in need.
Read Announcement- Drug:
- CASGEVY
- Announced Date:
- June 14, 2024
- Indication:
- For the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
Announcement
Vertex Pharmaceuticals Incorporated announced longer-term data for CASGEVY™ (exagamglogene autotemcel [exa-cel]) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT).
AI Summary
Vertex Pharmaceuticals announced longer-term data on CASGEVY™ (exagamglogene autotemcel) from global clinical trials in patients with severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The data, with follow-up of more than five years from the CLIMB studies, show that CASGEVY offers transformative, consistent, and durable clinical benefits. Patients experienced sustained levels of fetal hemoglobin and stable gene editing in their hematopoietic stem cells, leading to significant reductions in vaso-occlusive crises for SCD and maintained transfusion independence in TDT. The therapy’s safety profile remains in line with expectations for busulfan conditioning and autologous stem cell transplant. These promising long-term results support CASGEVY’s potential as a life-changing treatment option for patients with these serious blood disorders.
Read Announcement
ALYFTREK FDA Regulatory Events
ALYFTREK is a drug developed by Vertex Pharmaceuticals for the following indication: the treatment of people with cystic fibrosis.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- ALYFTREK
- Announced Date:
- April 1, 2026
- Indication:
- the treatment of people with cystic fibrosis
Announcement
Vertex Pharmaceuticals Incorporated announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein.
AI Summary
Vertex Pharmaceuticals announced the FDA has approved expanded use of ALYFTREK (vanzacaftor/tezacaftor/ivacaftor) for people with cystic fibrosis ages 6 and older who have a CFTR gene variant that is either shown to be responsive by clinical or in vitro data or that results in production of CFTR protein. The expansion means any variant that produces CFTR protein is now included in the indication for both ALYFTREK and TRIKAFTA, regardless of where the variant is located in the CFTR protein. About 800 more people with CF in the U.S. are now eligible for a CFTR modulator for the first time.
Key safety points: there is a warning for drug‑induced liver injury and potential liver failure—elevated liver enzymes have been reported and treatment should be interrupted for significant LFT rises or signs of liver injury, with close monitoring and possible hepatology referral. Post‑marketing hypersensitivity, including angioedema and anaphylaxis, has been reported. Dose changes are needed with strong or moderate CYP3A inhibitors/inducers, pediatric cataract monitoring is recommended, and safety in children under 6 for ALYFTREK (and under 2 for TRIKAFTA) is not established.
Read Announcement
Povetacicept FDA Regulatory Timeline and Events
Povetacicept is a drug developed by Vertex Pharmaceuticals for the following indication: in IgA nephropathy.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- povetacicept
- Announced Date:
- March 9, 2026
- Indication:
- in IgA nephropathy
Announcement
Vertex Pharmaceuticals Incorporated announced positive data from a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN).
AI Summary
Vertex reported positive Week 36 interim results from the Phase 3 RAINIER trial of povetacicept, an engineered dual BAFF/APRIL inhibitor, in immunoglobulin A nephropathy (IgAN). For the primary endpoint, povetacicept reduced 24‑hour urine protein to creatinine ratio (UPCR) by 52.0% from baseline and achieved a 49.8% greater reduction versus placebo (P<0.0001). Key secondary outcomes also favored treatment: serum Gd‑IgA1 fell 77.4% from baseline (79.3% versus placebo, P<0.0001), and 85.1% of treated patients achieved hematuria resolution, a 61.7% improvement versus placebo (P<0.0001).
Povetacicept was generally safe and well tolerated. Most adverse events were mild to moderate. There were no deaths, no opportunistic infections, and no discontinuations due to infection. Anti‑drug antibodies were observed but did not affect efficacy or safety. Serious adverse events occurred in 3.0% of povetacicept patients versus 4.3% with placebo; infection SAEs were 0.5% in both groups. Treatment and trial discontinuations were lower with povetacicept.
Vertex plans to complete a Biologics License Application by the end of March for potential U.S. Accelerated Approval. The blinded RAINIER trial will continue to a final two‑year analysis of eGFR slope. Povetacicept remains investigational.
Read Announcement- Drug:
- povetacicept
- Announced Date:
- November 8, 2025
- Indication:
- in IgA nephropathy
Announcement
Vertex Pharmaceuticals Incorporated nnounced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas. Pove is an investigational recombinant fusion protein therapeutic and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases.
AI Summary
Vertex presented updated RUBY-3 data at ASN Kidney Week 2025 for povetacicept (pove), an investigational recombinant fusion protein that blocks both BAFF and APRIL. Pove is the only BAFF+APRIL inhibitor currently in pivotal trials for multiple kidney diseases. The reported data come from the open‑label Phase 1/2 RUBY‑3 80 mg cohort (21 people with IgA nephropathy and 10 with primary membranous nephropathy).
At 48 weeks, mean 24‑hour urine protein‑to‑creatinine ratio fell 64% in IgA nephropathy and 82% in primary membranous nephropathy. eGFR was stable in both groups (change: +3.3±3.1 mL/min/1.73 m2 in IgAN; −0.3±3.4 in pMN). Among those with moderate/large baseline blood in urine, 90% had hematuria resolution. Clinical remission rates were 53% in IgAN and 40% complete remission in pMN.
Pove was generally well tolerated; adverse events were mostly mild or moderate and no serious adverse events were attributed to the drug. Vertex noted the global Phase 3 RAINIER study in IgAN is fully enrolled and a pivotal Phase 2/3 pMN trial is underway.
Read Announcement- Drug:
- povetacicept
- Announced Date:
- October 17, 2025
- Indication:
- in IgA nephropathy
Announcement
Vertex Pharmaceuticals Incorporated announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases.
AI Summary
Vertex Pharmaceuticals announced key updates for povetacicept (pove), an experimental fusion protein that blocks two immune proteins, BAFF and APRIL. Pove has shown best-in-class potential in two serious kidney diseases—IgA nephropathy (IgAN) and primary membranous nephropathy (pMN)—and may help other B cell–driven conditions.
In IgAN, the FDA has granted a rolling review of the Biologics License Application. Vertex plans to submit the first module by the end of 2025 and aims to complete the full submission in the first half of 2026, assuming positive interim results.
For pMN, Vertex has started the OLYMPUS Phase 2b/3 study, its second pivotal trial, to test pove’s ability to induce clinical remission over two years.
Data from the RUBY-3 trial in IgAN and pMN, along with other kidney disease research, will be shared at ASN Kidney Week 2025 in Houston.
Read Announcement
Vanzacaftor/Tezacaftor/Deutivacaftor, FDA Regulatory Timeline and Events
Vanzacaftor/Tezacaftor/Deutivacaftor, is a drug developed by Vertex Pharmaceuticals for the following indication: For people living with cystic fibrosis (CF).
This drug is approved by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- Vanzacaftor/Tezacaftor/Deutivacaftor,
- Announced Date:
- October 23, 2025
- Indication:
- For people living with cystic fibrosis (CF)
Announcement
Vertex Pharmaceuticals Incorporated announced the presentation of multiple abstracts demonstrating the clinical benefits of treatment with CFTR modulators, including the Company's most recently approved medicine, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), at the North American Cystic Fibrosis Conference (NACFC) held from October 22-25 in Seattle, Washington.
AI Summary
Vertex Pharmaceuticals presented new data at the North American Cystic Fibrosis Conference (NACFC) from October 22–25 in Seattle. The company showcased multiple abstracts highlighting the benefits of its CFTR modulators, especially its newest therapy, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor). These studies link greater reductions in sweat chloride levels to better health outcomes in people with cystic fibrosis (CF).
In Phase 3 trials, ALYFTREK demonstrated larger drops in sweat chloride compared to TRIKAFTA®, suggesting it could offer more improvements in lung function, quality of life, and fewer pulmonary exacerbations. One poster (868) showed lower rates of respiratory flare-ups and IV antibiotic use in patients with F508del-minimal function genotypes treated with ALYFTREK.
Another analysis (Poster 119) found that children aged 6–11 who began modulator therapy earlier achieved greater CFTR function and saw gains in lung health, nutrition, and reduced exacerbations. Overall, Vertex’s NACFC presentations reinforce that stronger sweat chloride reduction with ALYFTREK may lead to meaningful clinical benefits for people with CF.
Read Announcement- Drug:
- Vanzacaftor/Tezacaftor/Deutivacaftor,
- Announced Date:
- June 6, 2025
- Indication:
- For people living with cystic fibrosis (CF)
Announcement
Vertex Pharmaceuticals Incorporated announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland.
AI Summary
Vertex Pharmaceuticals recently shared promising data from several studies showing that treatment with CFTR modulators can lead to meaningful clinical benefits for cystic fibrosis patients. In particular, ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) demonstrated improvements in patient quality of life and other health measures. The data showed that lower sweat chloride levels, which indicate better CFTR function, were linked to enhanced lung performance, improved nutrition, and fewer pulmonary exacerbations.
Additional analyses from phase 3 trials revealed that ALYFTREK provided superior quality of life outcomes compared to TRIKAFTA, especially among adolescents, adults, and children. While ALYFTREK is already approved in the United States and United Kingdom, it is currently under review by health authorities in the EU, Canada, Australia, New Zealand, and Switzerland.
Read Announcement- Drug:
- Vanzacaftor/Tezacaftor/Deutivacaftor,
- Announced Date:
- January 12, 2025
- Indication:
- For people living with cystic fibrosis (CF)
Announcement
Vertex Pharmaceuticals Incorporated announced multiple program updates
AI Summary
Vertex Pharmaceuticals announced multiple program updates ahead of upcoming investor meetings, emphasizing its plans for growth and further diversification in 2025. CEO Reshma Kewalramani highlighted that 2024 was a pivotal year, with the company expanding patient access and launching new initiatives. Looking ahead, Vertex aims to diversify revenue with new launches in cystic fibrosis, cell therapies for blood disorders, treatments for acute pain, and studies in kidney diseases, type 1 diabetes, and other areas. The company is progressing several clinical stage programs and expects new data from ongoing trials, which could support additional transformative therapies. Vertex also plans to broaden its commercial and clinical presence worldwide. More details are anticipated during a scheduled webcast at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025.
Read Announcement- Drug:
- Vanzacaftor/Tezacaftor/Deutivacaftor,
- Announced Date:
- December 20, 2024
- Indication:
- For people living with cystic fibrosis (CF)
Announcement
Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning.
AI Summary
Vertex Pharmaceuticals announced that the FDA has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily triple combination CFTR modulator for treating cystic fibrosis. This approval is for patients aged 6 years and older who have at least one F508del mutation or any other mutation in the CFTR gene that responds to ALYFTREK, including 31 additional mutations not treated by previous therapies.
ALYFTREK demonstrated effectiveness in clinical trials by meeting key endpoints, such as non-inferiority in lung function (ppFEV1) and a significant decrease in sweat chloride levels compared to TRIKAFTA®. The treatment offers the convenience of once-daily dosing, which addresses a high unmet need among physicians. However, its use comes with important safety information, including a Boxed Warning for drug-induced liver injury and liver failure, underscoring the need for careful patient monitoring.
Read Announcement- Drug:
- Vanzacaftor/Tezacaftor/Deutivacaftor,
- Announced Date:
- September 26, 2024
- Indication:
- For people living with cystic fibrosis (CF)
Announcement
Vertex Pharmaceuticals Incorporated announced the first accepted medical presentations of the Phase 3 data on the investigational once daily vanzacaftor/tezacaftor/deutivacaftor ("vanza triple") — the potential next-in-class triple combination medicine — will take place at the North American Cystic Fibrosis Conference (NACFC). Vertex also announced presentations describing long-term outcomes in people with cystic fibrosis (CF) ages 2 to 11 years taking TRIKAFTA®, demonstrating consistent and sustained improvements across multiple
AI Summary
Vertex Pharmaceuticals announced that it will present Phase 3 data on its investigational once daily triple combination therapy vanzacaftor/tezacaftor/deutivacaftor, also known as "vanza triple," at the North American Cystic Fibrosis Conference (NACFC). This medicine, potentially next-in-class, has shown non-inferiority to TRIKAFTA® in improving lung function (ppFEV1) and has resulted in further reductions in sweat chloride levels, suggesting enhanced CFTR function. Additionally, Vertex will showcase long-term outcomes in children aged 2 to 11 years who are treated with TRIKAFTA®. The data indicate that early treatment leads to sustained improvements in lung function and may even enhance exocrine pancreatic function over time. These presentations highlight Vertex’s commitment to advancing cystic fibrosis treatment and supporting improved clinical outcomes for patients across various age groups.
Read Announcement
Inaxaplin FDA Regulatory Events
Inaxaplin is a drug developed by Vertex Pharmaceuticals for the following indication: APOL1-mediated kidney disease.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- inaxaplin
- Announced Date:
- September 25, 2025
- Indication:
- APOL1-mediated kidney disease
Announcement
Vertex Pharmaceuticals Incorporated announced several important advancements across its programs in immunoglobulin A Nephropathy (IgAN), APOL1-mediated kidney disease (AMKD) and autosomal dominant polycystic kidney disease (ADPKD).
AI Summary
Vertex Pharmaceuticals announced progress in three kidney disease programs: immunoglobulin A nephropathy (IgAN), APOL1-mediated kidney disease (AMKD), and autosomal dominant polycystic kidney disease (ADPKD).
In IgAN, the FDA granted Breakthrough Therapy Designation for povetacicept, a dual BAFF/APRIL antagonist. RAINIER Phase 3 has enrolled the 36-week interim cohort. Vertex may seek U.S. accelerated approval in H1 2026 if results are positive.
In AMKD, enrollment is complete for the AMPLITUDE Phase 2/3 interim cohort of inaxaplin, a first-in-class APOL1 inhibitor. At Week 48, Vertex will assess proteinuria and kidney function and could seek U.S. accelerated approval if data are favorable.
In ADPKD, Vertex launched AGLOW, a Phase 2 study of VX-407. This small-molecule corrector targets PC1 folding in patients with PKD1 variants. Over 52 weeks, it will track total kidney volume changes to explore disease modification.
Read Announcement
VX-993 FDA Regulatory Events
VX-993 is a drug developed by Vertex Pharmaceuticals for the following indication: For the Treatment of Acute Pain.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- VX-993
- Announced Date:
- August 4, 2025
- Indication:
- For the Treatment of Acute Pain
Announcement
Vertex Pharmaceuticals Incorporated announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ranging study evaluating the safety and efficacy of its investigational selective NaV1.8 pain signal inhibitor, VX-993, in treating acute pain after bunionectomy surgery.
AI Summary
Vertex announced topline results from its Phase 2 study testing VX-993, a selective NaV1.8 pain signal inhibitor, for acute pain after bunionectomy. In the randomized, double-blind, placebo-controlled trial of 367 patients, VX-993 did not significantly improve pain scores over 48 hours (SPID48) compared to placebo.
VX-993 was generally safe and well tolerated. Most side effects, such as nausea and headache, were mild to moderate and occurred at rates similar to placebo. No serious adverse events were linked to the drug, and no patients stopped treatment because of side effects.
Based on these results and earlier data, Vertex will not advance VX-993 as a monotherapy for acute pain. “VX-993 is not expected to be superior to our existing NaV1.8 inhibitors,” said Carmen Bozic, M.D., Vertex’s Chief Medical Officer.
Read Announcement
Exagamglogene autotemcel FDA Regulatory Events
Exagamglogene autotemcel is a drug developed by Vertex Pharmaceuticals for the following indication: For severe sickle cell disease.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- exagamglogene autotemcel
- Announced Date:
- July 3, 2025
- Indication:
- For severe sickle cell disease
Announcement
Vertex Pharmaceuticals announced positive longer-term data for PrCASGEVY® (exagamglogene autotemcel) from global ongoing pivotal clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT).
AI Summary
Vertex Pharmaceuticals announced positive longer-term data for PrCASGEVY® (exagamglogene autotemcel) from global clinical trials conducted in patients with severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The results show that the clinical benefits of CASGEVY have been durable, with SCD patients followed for over 5.5 years and TDT patients for more than 6 years. In the trials, nearly all SCD patients experienced a long period without painful vaso-occlusive crises and hospitalizations, while almost all TDT patients maintained transfusion independence with improved hemoglobin levels.
These findings highlight the potential of CASGEVY, a CRISPR/Cas9 gene-edited therapy, to offer long-lasting relief for individuals with these severe blood disorders. Vertex is working with reimbursement authorities globally to expand access to this treatment for more eligible patients.
Read Announcement
VX-880 FDA Regulatory Timeline and Events
VX-880 is a drug developed by Vertex Pharmaceuticals for the following indication: 1 diabetes (T1D) with severe hypoglycemia and impaired hypoglycemic awareness.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- VX-880
- Announced Date:
- June 20, 2025
- Indication:
- 1 diabetes (T1D) with severe hypoglycemia and impaired hypoglycemic awareness
Announcement
Vertex Pharmaceuticals Incorporated announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs).
AI Summary
Vertex Pharmaceuticals announced updated data from the Phase 1/2 portion of its FORWARD-101 clinical trial for zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy for type 1 diabetes patients with impaired hypoglycemic awareness and severe hypoglycemic events. The trial involved 12 patients who received a full dose in a single infusion and were followed for at least one year. All patients reached ADA-recommended targets with HbA1c levels below 7% and over 70% time in the target glucose range, while 10 of the 12 participants became insulin free by Month 12. In addition to a significant mean reduction (92%) in daily insulin usage, patients also showed durable glucose-responsive C-peptide production. The results, presented at the ADA annual conference and published in the New England Journal of Medicine, emphasize zimislecel’s transformative potential and support Vertex’s plans to complete broader trial enrollment.
Read Announcement- Drug:
- VX-880
- Announced Date:
- March 28, 2025
- Indication:
- 1 diabetes (T1D) with severe hypoglycemia and impaired hypoglycemic awareness
Announcement
Vertex Pharmaceuticals Incorporated announced several updates on the Company's type 1 diabetes (T1D) portfolio.
AI Summary
Vertex Pharmaceuticals has shared key updates on its type 1 diabetes (T1D) portfolio. In the Phase 1/2 VX-264 study, enrollment and dosing for Parts A and B have been completed. Although VX-264, which combines cells with a proprietary immunoprotective device, was generally safe and well tolerated, it did not meet the efficacy endpoint as the expected increase in C-peptide levels was not achieved. As a result, the company will not move forward with additional clinical trials for VX-264.
Meanwhile, the zimislecel (VX-880) program is advancing into its pivotal Phase 3 trial targeting patients experiencing severe hypoglycemic events. Enrollment and dosing are on track to finish in the first half of 2025, with global regulatory submissions planned for 2026. Vertex is also exploring other immunoprotective approaches that could transform treatment options for patients with T1D.
Read Announcement- Drug:
- VX-880
- Announced Date:
- June 21, 2024
- Indication:
- 1 diabetes (T1D) with severe hypoglycemia and impaired hypoglycemic awareness
Announcement
Vertex Pharmaceuticals Incorporated today presented new data from its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs).
AI Summary
Vertex Pharmaceuticals shared promising Phase 1/2 clinical trial data on VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy designed for people with type 1 diabetes who struggle with impaired hypoglycemic awareness and severe low blood sugar events. In the data from 12 patients who received a full-dose single infusion, all participants exhibited islet cell engraftment and began producing glucose-responsive insulin by Day 90. Furthermore, every patient achieved the recommended HbA1c target of less than 7.0% and maintained over 70% time-in-range on continuous glucose monitoring, with 11 of 12 reducing or stopping their use of exogenous insulin. Notably, three patients with at least a 12-month follow-up reached key endpoints, including the elimination of severe hypoglycemic episodes and insulin independence. These results support VX-880’s potential to transform treatment for type 1 diabetes and have encouraged further study expansion.
Read Announcement
Vanza triple FDA Regulatory Events
Vanza triple is a drug developed by Vertex Pharmaceuticals for the following indication: Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- vanza triple
- Announced Date:
- July 2, 2024
- Indication:
- Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis
Announcement
Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for investigational once-daily vanzacaftor/tezacaftor/deutivacaftor triple combination therapy (vanza triple) for people living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene responsive to the vanza triple.
AI Summary
Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for the investigational once-daily vanzacaftor/tezacaftor/deutivacaftor triple combination therapy, also known as vanza triple. This therapy is aimed at treating people with cystic fibrosis (CF) aged 6 years and older who have at least one F508del mutation or another mutation responsive to the treatment. Vertex used a priority review voucher for this submission, shortening the review time from 10 months to 6 months, setting a Prescription Drug User Fee Act (PDUFA) target action date of January 2, 2025. The FDA acceptance represents an important regulatory milestone in improving CF care by potentially lowering sweat chloride levels, a key indicator in CF management. Additionally, the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) submission, reflecting the broad international interest in vanza triple’s potential.
Read Announcement- Drug:
- vanza triple
- Announced Date:
- July 2, 2024
- Indication:
- Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis
Announcement
Vertex used a priority review voucher for this submission reducing the review time from 10 months to 6 months, resulting in a Prescription Drug User Fee Act (PDUFA) target action date of January 2, 2025.
AI Summary
Vertex Pharmaceuticals has received FDA acceptance for its New Drug Application for the investigational vanza triple therapy for cystic fibrosis. Notably, Vertex used a priority review voucher for this submission, cutting the review time from the standard 10 months to just 6 months. As a result, the FDA set the Prescription Drug User Fee Act (PDUFA) target action date for January 2, 2025. This accelerated review process is an important step in Vertex’s efforts to bring new treatment options to people with CF aged 6 and older who have at least one F508del mutation or another responsive mutation.
The fast-track approach underscores Vertex’s commitment to innovation in CF treatment. By streamlining the review process, the company aims to speed up access to its promising therapy, potentially offering significant benefits to those living with cystic fibrosis.
Read Announcement
